Skip to main content
Ildiko Csiki, MD, Radiology, Philadelphia, PA

IldikoCsikiMD

Radiology Philadelphia, PA

Ultrasound

Assistant Professor, Radiation Oncology, Perelman School of Medicine

Dr. Csiki is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Csiki's full profile

Already have an account?

Education & Training

  • Vanderbilt University
    Vanderbilt UniversityResidency, Radiation Oncology, 2008 - 2012
  • Vanderbilt University
    Vanderbilt UniversityInternship, Internal Medicine, 2007 - 2008
  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineClass of 2007

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Press Mentions

  • Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-301 in Patients with ASPH-Positive Head and Neck Cancer
    Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-301 in Patients with ASPH-Positive Head and Neck CancerNovember 18th, 2019
  • Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting
    Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual MeetingApril 1st, 2019
  • Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen
    Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific AntigenNovember 19th, 2018
  • Join now to see all